Cardaioli P, Compostella L, De Domenico R, Papalia D, Zeppellini R, Libardoni M, Pulido E, Cucchini F
G Ital Cardiol. 1986 Mar;16(3):237-40.
It is well known that many cardiovascular drugs affect digoxin kinetics, but nothing is defined on propafenone-digoxin interaction. To clarify this problem, we studied digoxin kinetics in 8 healthy men, who received digoxin oral dose (0.50 mg) in the control state and again during maintenance therapy with propafenone (150 mg q.i.d.). Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005). Renal digoxin clearance was not affected by propafenone. We conclude that propafenone interact kinetically with digoxin in healthy subjects, perhaps increasing digoxin bioavailability.
众所周知,许多心血管药物会影响地高辛的动力学,但关于普罗帕酮与地高辛相互作用尚无定论。为阐明这一问题,我们对8名健康男性进行了地高辛动力学研究,这些受试者在对照状态下口服地高辛剂量(0.50毫克),并在普罗帕酮维持治疗期间(150毫克,每日4次)再次口服。在普罗帕酮治疗期间,观察到一些地高辛动力学指标有统计学显著变化:血清地高辛峰值浓度升高(4.30对3.07纳克/毫升 - p小于0.005),血清地高辛浓度曲线下面积(4小时:520.4对368.9;10小时:789.6对621.3纳克·分钟/毫升 - p小于0.005;24小时:1187.6对954.7纳克·分钟/毫升 - p小于0.05)以及地高辛的尿排泄量(277.7对203.5微克 - p小于0.005)。普罗帕酮不影响地高辛的肾清除率。我们得出结论,在健康受试者中,普罗帕酮与地高辛在动力学上相互作用,可能增加了地高辛的生物利用度。